Explore the latest in research, methods, and statistics, including topics in clinical research infrastructure, design, conduct, and analysis.
This Viewpoint summarizes a 2018 National Academies of Sciences, Engineering, and Medicine (NASEM) report that details challenges to support of biomedical scientists in the United States and proposes solutions, including public-private partnerships and a dedicated line of Congressional funding to support next-generation researchers and innovation.
This article explores cultural bias in medical research and care and the need for a more diverse community of physician-scientists.
This JAMA Guide to Statistics and Methods explains the rationale for permuted block randomization and for stratifying randomization in clinical trials.
This Viewpoint proposes strategies to manage code linkage gaps and other sources of error in the transition in the United States from use of the International Classification of Diseases, Ninth Revision (ICD-9) to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10).
This study examines the frequency of steroid use for acute respiratory tract infections in Louisiana and nationally, and factors associated with this clinical practice.
This qualitative study describes the perceptions of primary care practitioners on the use of an electronic consult system for specialty referrals in a safety-net health system.
This Viewpoint evaluates whether there is benefit for medical centers to advertise the opportunity for clinical trial participation.
This study assesses whether estimates from the new American College of Surgeons Surgical Risk Calculator more closely match residents’ estimations of risk and determines outcomes of similar patients in the National Surgical Quality Improvement Project.
This Viewpoint describes 4 major barriers to useful risk prediction that may not be easily overcome by new methods in machine learning and, in some instances, may be more difficult to overcome in the era of big data.
This Viewpoint reviews the rationale for measuring health outcomes using quality-adjusted life-years (QALYs) and discusses the advantages and limitations of the measure and its role in attempts to define and promote the practice of high-value medicine.
This Viewpoint proposes a system for ranking the quality of risk adjustment methods as a way to more accurately account for health care quality and more transparently link payment incentives to performance and patient outcomes.
This study characterizes the sources of funding for the research included in systematic reviews that form the basis for US Preventive Services Task Force recommendation statements.
In this Viewpoint, Insel and colleagues discuss the roles that private sector companies and foundations might play and the advantages of public-private partnerships in nurturing new and early-career physician-investigators given an always-challenging funding environment and ever-increasing hurdles young physicians must overcome to establish a research career.
This observational study examines whether drug discontinuation, effectiveness, and rates of serious adverse events differ in patients with psoriasis being treated with biologics who have been categorized as eligible or ineligible for clinical trials.
This special communication discusses the current ethical, legal, and social implications of sharing genomic and associated clinical data involving children.
This study summarizes policies of the top 20 noncommercial funders of health research regarding trial registration, access to summary results, and individual patient data availability.
This propensity score–matched cohort study examines whether adjuvant chemotherapy is associated with improved overall survival in patients with rectal cancer and pathological complete response following neoadjuvant chemoradiation therapy and resection.
This propensity score matching cohort analysis compares the overall survival between adjuvant chemotherapy and postoperative observation in patients with rectal cancer with pathologic complete response following neoadjuvant chemoradiotherapy and resection.
This Viewpoint discusses the need to refine existing guidance to clarify the broad acceptability of offering all types of payment to research participants to reduce financial burden for patients.
Customize your JAMA Network experience by selecting one or more topics from the list below.